Compare $IMNM vs $VRDN | Chartloom

Compare

$IMNM vs $VRDN

Immunome Inc · Viridian Therapeutics Inc

IMNM

Immunome Inc

VRDN

Viridian Therapeutics Inc

Compare $IMNM vs $VRDN

Comparing Immunome Inc and Viridian Therapeutics Inc

IMNMImmunome Inc

VRDNViridian Therapeutics Inc

IMNMImmunome Inc

Market cap

$2.21B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

127.50x

Rev growth (TTM)

-100.0%

YTD performance

-6.1%

52W performance

39.5%

FCF yield

-10.3%

VRDNViridian Therapeutics Inc

Market cap

$2.06B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

14.59x

Rev growth (TTM)

23220.3%

YTD performance

-39.2%

52W performance

-12.6%

FCF yield

-16.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

IMNM

VRDN

Detailed metrics comparison

IMNM

Immunome Inc

VRDN

Viridian Therapeutics Inc

Market Cap

IMNM$2.21B

VRDN$2.06B

Enterprise Value

IMNM$2.00B

VRDN$2.25B

Price

IMNM$19.55

VRDN$18.66

P/E Ratio

IMNMN/A

VRDNN/A

P/S Ratio

IMNM188.56x

VRDN28.97x

EV/Sales

IMNM171.27x

VRDN31.65x

EV/EBITDA

IMNM0.00x

VRDN0.00x

P/B Ratio

IMNM4.52x

VRDN3.58x

P/FCF Ratio

IMNMN/A

VRDNN/A

EV/FCF

IMNM-8.75x

VRDN-6.72x

PEG Ratio

IMNMN/A

VRDNN/A

Forward P/E (NTM)

IMNMN/A

VRDNN/A

Forward P/S (NTM)

IMNM127.50x

VRDN14.59x

Revenue (TTM)

IMNM$0

VRDN$71M

Revenue Growth (YoY)

IMNM-100.0%

VRDN23220.3%

Forward Rev Growth

IMNM15247.2%

VRDN729.0%

Gross Margin (TTM)

IMNM0.0%

VRDN2.4%

Operating Margin (TTM)

IMNM0.0%

VRDN0.0%

EBITDA Margin (TTM)

IMNM0.0%

VRDN-569.0%

Net Margin (TTM)

IMNM0.0%

VRDN-544.1%

FCF Margin (TTM)

IMNMN/A

VRDN-471.0%

Net Income (TTM)

IMNM$-254M

VRDN$-387M

FCF (TTM)

IMNM$-228M

VRDN$-335M

EPS (TTM)

IMNM-$2.25

VRDN-$3.59

ROE (TTM)

IMNM-5056.0%

VRDN-6135.0%

ROA (TTM)

IMNM-4693.0%

VRDN-4603.0%

ROIC (TTM)

IMNM-5056.0%

VRDN-5041.0%

Cash

IMNM$218M

VRDN$165M

Debt

IMNM$0

VRDN$356M

Net Cash/Debt

IMNM$218M

VRDN$-191M

Current Ratio (TTM)

IMNM15.08x

VRDN16.95x

Quick Ratio (TTM)

IMNM14.56x

VRDN16.56x

Debt/Equity (TTM)

IMNM0.00x

VRDN0.54x

Debt/Assets (TTM)

IMNM0.0%

VRDN0.0%

Interest Coverage (TTM)

IMNMN/A

VRDNN/A

Net Debt/EBITDA (TTM)

IMNM0.00x

VRDN0.00x

Beta

IMNM2.65

VRDN1.11

52W Performance

IMNM39.5%

VRDN-12.6%

YTD Performance

IMNM-6.1%

VRDN-39.2%

% from 52W High

IMNM-35.0%

VRDN-45.6%

% from 52W Low

IMNM44.9%

VRDN41.6%

Asset Turnover (TTM)

IMNM0.04x

VRDN0.08x

FCF Yield (TTM)

IMNM-10.3%

VRDN-16.3%

Earnings Yield (TTM)

IMNM-11.5%

VRDN-18.8%

Dividend Yield (TTM)

IMNMN/A

VRDNN/A

Rule of 40

IMNM-100.0

VRDN22,749.3

EV/GP/RG

IMNMN/A

VRDN8.67

Ticker research

View IMNM research View VRDN research

Metric	IMNM Immunome Inc	VRDN Viridian Therapeutics Inc
Market & Valuation
Market Cap	$2.21B	$2.06B
Enterprise Value	$2.00B	$2.25B
Price	$19.55	$18.66
P/E Ratio	N/A	N/A
P/S Ratio	188.56x	28.97x
EV/Sales	171.27x	31.65x
EV/EBITDA	0.00x	0.00x
P/B Ratio	4.52x	3.58x
P/FCF Ratio	N/A	N/A
EV/FCF	-8.75x	-6.72x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	127.50x	14.59x
Revenue & Growth
Revenue (TTM)	$0	$71M
Revenue Growth (YoY)	-100.0%	23220.3%
Forward Rev Growth	15247.2%	729.0%
Profitability
Gross Margin (TTM)	0.0%	2.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-569.0%
Net Margin (TTM)	0.0%	-544.1%
FCF Margin (TTM)	N/A	-471.0%
Net Income (TTM)	$-254M	$-387M
FCF (TTM)	$-228M	$-335M
EPS (TTM)	-$2.25	-$3.59
ROE (TTM)	-5056.0%	-6135.0%
ROA (TTM)	-4693.0%	-4603.0%
ROIC (TTM)	-5056.0%	-5041.0%
Financial Health
Cash	$218M	$165M
Debt	$0	$356M
Net Cash/Debt	$218M	$-191M
Current Ratio (TTM)	15.08x	16.95x
Quick Ratio (TTM)	14.56x	16.56x
Debt/Equity (TTM)	0.00x	0.54x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.65	1.11
52W Performance	39.5%	-12.6%
YTD Performance	-6.1%	-39.2%
% from 52W High	-35.0%	-45.6%
% from 52W Low	44.9%	41.6%
Efficiency & Yields
Asset Turnover (TTM)	0.04x	0.08x
FCF Yield (TTM)	-10.3%	-16.3%
Earnings Yield (TTM)	-11.5%	-18.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-100.0	22,749.3
EV/GP/RG	N/A	8.67
Ticker research	View IMNM research	View VRDN research

Valuation

P/S Ratio

VRDN

28.97x

IMNM

188.56x

EV/FCF

IMNM

-8.75x

VRDN

-6.72x

Growth & revenue

Revenue Growth TTM

VRDN

23220.3%

IMNM

-100.0%

Forward Revenue Growth

IMNM

15247.2%

VRDN

729.0%

Profitability & performance

Gross Margin

VRDN

2.4%

IMNM

0.0%

ROE

IMNM

-5056.0%

VRDN

-6135.0%

FCF Yield %

IMNM

-10.3%

VRDN

-16.3%

52-Week Performance

IMNM

39.5%

VRDN

-12.6%

Detailed metrics comparison

IMNM

Immunome Inc

VRDN

Viridian Therapeutics Inc

Market Cap

IMNM$2.21B

VRDN$2.06B

Enterprise Value

IMNM$2.00B

VRDN$2.25B

Price

IMNM$19.55

VRDN$18.66

P/E Ratio

IMNMN/A

VRDNN/A

P/S Ratio

IMNM188.56x

VRDN28.97x

EV/Sales

IMNM171.27x

VRDN31.65x

EV/EBITDA

IMNM0.00x

VRDN0.00x

P/B Ratio

IMNM4.52x

VRDN3.58x

P/FCF Ratio

IMNMN/A

VRDNN/A

EV/FCF

IMNM-8.75x

VRDN-6.72x

PEG Ratio

IMNMN/A

VRDNN/A

Forward P/E (NTM)

IMNMN/A

VRDNN/A

Forward P/S (NTM)

IMNM127.50x

VRDN14.59x

Revenue (TTM)

IMNM$0

VRDN$71M

Revenue Growth (YoY)

IMNM-100.0%

VRDN23220.3%

Forward Rev Growth

IMNM15247.2%

VRDN729.0%

Gross Margin (TTM)

IMNM0.0%

VRDN2.4%

Operating Margin (TTM)

IMNM0.0%

VRDN0.0%

EBITDA Margin (TTM)

IMNM0.0%

VRDN-569.0%

Net Margin (TTM)

IMNM0.0%

VRDN-544.1%

FCF Margin (TTM)

IMNMN/A

VRDN-471.0%

Net Income (TTM)

IMNM$-254M

VRDN$-387M

FCF (TTM)

IMNM$-228M

VRDN$-335M

EPS (TTM)

IMNM-$2.25

VRDN-$3.59

ROE (TTM)

IMNM-5056.0%

VRDN-6135.0%

ROA (TTM)

IMNM-4693.0%

VRDN-4603.0%

ROIC (TTM)

IMNM-5056.0%

VRDN-5041.0%

Cash

IMNM$218M

VRDN$165M

Debt

IMNM$0

VRDN$356M

Net Cash/Debt

IMNM$218M

VRDN$-191M

Current Ratio (TTM)

IMNM15.08x

VRDN16.95x

Quick Ratio (TTM)

IMNM14.56x

VRDN16.56x

Debt/Equity (TTM)

IMNM0.00x

VRDN0.54x

Debt/Assets (TTM)

IMNM0.0%

VRDN0.0%

Interest Coverage (TTM)

IMNMN/A

VRDNN/A

Net Debt/EBITDA (TTM)

IMNM0.00x

VRDN0.00x

Beta

IMNM2.65

VRDN1.11

52W Performance

IMNM39.5%

VRDN-12.6%

YTD Performance

IMNM-6.1%

VRDN-39.2%

% from 52W High

IMNM-35.0%

VRDN-45.6%

% from 52W Low

IMNM44.9%

VRDN41.6%

Asset Turnover (TTM)

IMNM0.04x

VRDN0.08x

FCF Yield (TTM)

IMNM-10.3%

VRDN-16.3%

Earnings Yield (TTM)

IMNM-11.5%

VRDN-18.8%

Dividend Yield (TTM)

IMNMN/A

VRDNN/A

Rule of 40

IMNM-100.0

VRDN22,749.3

EV/GP/RG

IMNMN/A

VRDN8.67

Ticker research

View IMNM research View VRDN research

Metric	IMNM Immunome Inc	VRDN Viridian Therapeutics Inc
Market & Valuation
Market Cap	$2.21B	$2.06B
Enterprise Value	$2.00B	$2.25B
Price	$19.55	$18.66
P/E Ratio	N/A	N/A
P/S Ratio	188.56x	28.97x
EV/Sales	171.27x	31.65x
EV/EBITDA	0.00x	0.00x
P/B Ratio	4.52x	3.58x
P/FCF Ratio	N/A	N/A
EV/FCF	-8.75x	-6.72x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	127.50x	14.59x
Revenue & Growth
Revenue (TTM)	$0	$71M
Revenue Growth (YoY)	-100.0%	23220.3%
Forward Rev Growth	15247.2%	729.0%
Profitability
Gross Margin (TTM)	0.0%	2.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-569.0%
Net Margin (TTM)	0.0%	-544.1%
FCF Margin (TTM)	N/A	-471.0%
Net Income (TTM)	$-254M	$-387M
FCF (TTM)	$-228M	$-335M
EPS (TTM)	-$2.25	-$3.59
ROE (TTM)	-5056.0%	-6135.0%
ROA (TTM)	-4693.0%	-4603.0%
ROIC (TTM)	-5056.0%	-5041.0%
Financial Health
Cash	$218M	$165M
Debt	$0	$356M
Net Cash/Debt	$218M	$-191M
Current Ratio (TTM)	15.08x	16.95x
Quick Ratio (TTM)	14.56x	16.56x
Debt/Equity (TTM)	0.00x	0.54x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.65	1.11
52W Performance	39.5%	-12.6%
YTD Performance	-6.1%	-39.2%
% from 52W High	-35.0%	-45.6%
% from 52W Low	44.9%	41.6%
Efficiency & Yields
Asset Turnover (TTM)	0.04x	0.08x
FCF Yield (TTM)	-10.3%	-16.3%
Earnings Yield (TTM)	-11.5%	-18.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-100.0	22,749.3
EV/GP/RG	N/A	8.67
Ticker research	View IMNM research	View VRDN research